IP Library Granted Patent US 11,400,159
Granted Patent B2
US 11,400,159 · App. 16/990,071 · Granted Aug 2, 2022

Pharmaceutical compositions and related methods of delivery

Inventors: Roni Mamluk (Mazkeret Batya, IL); Moshe Tzabari (Jerusalem, IL); Karen Marom (Mevaseret Zion, IL); Paul Salama (Ashdod, IL); Irina Weinstein (Maale Adummim, IL)
Assignee: Amryt Endo, Inc.
A61K47/44A61K9/0031A61K9/0053A61K9/10A61K9/4858A61K9/4866A61K9/4891A61K31/70A61K31/7036A61K31/713A61K31/721A61K38/08A61K38/09A61K38/095A61K38/12A61K38/14A61K38/212A61K38/22A61K38/26A61K38/27A61K38/28A61K38/29A61K47/12A61K47/14A61K47/24A61K47/26A61K47/32A61K9/1623A61K51/083A61K51/1021A61K51/1024A61K51/1045
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 11,400,159
App. No.
16/990,071
Granted
Aug 2, 2022
Kind
B2
Abstract

The pharmaceutical compositions described herein include a suspension which comprises an admixture in solid form of a therapeutically effective amount of a therapeutic agent and at least one salt of a medium chain fatty acid and a hydrophobic medium, e.g. castor oil or glyceryl tricaprylate or a mixture thereof. The pharmaceutical compositions described herein contain medium chain fatty acid salts and are substantially free of alcohols. The pharmaceutical compositions may be encapsulated in a capsule. Methods of treating or preventing diseases by administering such compositions to affected subjects are also disclosed.

Claims (9)

1. A solid form comprising a plurality of particles, wherein the particles comprise octreotide, at least one salt of a medium chain fatty acid, and polyvinylpyrrolidone (PVP), wherein the medium chain fatty acid is present in the solid form at an amount of about 50% to about 90% by weight.

2. The solid form of claim 1 , wherein the PVP has a molecular weight of about 3000.

3. The solid form of claim 1 , wherein the medium chain fatty acid salt has a chain length from about 6 to about 14 carbon atoms.

4. The solid form of claim 3 , wherein the medium chain fatty acid salt is sodium hexanoate, sodium heptanoate, sodium octanoate, sodium nonanoate, sodium decanoate, sodium undecanoate, sodium dodecanoate, sodium tridecanoate or sodium tetradecanoate, or a corresponding potassium or lithium or ammonium salt or a combination thereof.

5. The solid form of claim 4 , wherein the medium chain fatty acid salt is sodium octanoate.

6. The solid form of claim 1 , wherein the medium chain fatty acid is present in the solid form at an amount of 70% to 80% by weight.

7. The solid form of claim 1 , wherein the medium chain fatty acid is present in the solid form at an amount of about 50% by weight.

8. The solid form of claim 1 , further comprising a stabilizer.

9. The solid form of claim 1 , wherein the solid form comprises water content of lower than 3% by weight in the solid form.

Assignments (6)
MERGER AND CHANGE OF NAME Recorded Jan 7, 2026
From: AMRYT ENDO, INC.; AMYRT PHARMACEUTICALS INC.
To: AMRYT PHARMACEUTICALS INC.
Reel/Frame 073389/0551 →
CHANGE OF ADDRESS Recorded Mar 19, 2024
From: MCEVOY, JOHN
To: AMRYT ENDO, INC.
Reel/Frame 066833/0786 →
RELEASE OF SECURITY INTEREST Recorded Apr 13, 2023
From: ARES CAPITAL CORPORATION, AS ADMINISTRATIVE AGENT
To: AMRYT GENETICS LIMITED; AMRYT PHARMACEUTICALS, INC.; AMRYT ENDO, INC.; AMRYT RESEARCH LIMITED
Reel/Frame 063318/0849 →
SECURITY INTEREST Recorded Feb 18, 2022
From: AMRYT ENDO, INC.
To: ARES CAPITAL CORPORATION, AS ADMINISTRATIVE AGENT
Reel/Frame 059048/0944 →
MERGER Recorded Nov 3, 2021
From: CHIASMA, INC.
To: AMRYT ENDO, INC.
Reel/Frame 058009/0027 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Nov 3, 2021
From: SALAMA, PAUL; MAMLUK, RONI; MAROM, KAREN; WEINSTEIN, IRINA; TZABARI, MOSHE
To: CHIASMA, INC.
Reel/Frame 058014/0883 →